Compare OOMA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ZURA |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 455.4M |
| IPO Year | 2015 | N/A |
| Metric | OOMA | ZURA |
|---|---|---|
| Price | $17.02 | $3.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $18.77 | $13.00 |
| AVG Volume (30 Days) | 304.4K | ★ 656.9K |
| Earning Date | 05-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | $75.17 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $1.00 |
| 52 Week High | $21.96 | $7.25 |
| Indicator | OOMA | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 25.83 |
| Support Level | $10.78 | $3.33 |
| Resistance Level | $19.56 | $4.12 |
| Average True Range (ATR) | 0.97 | 0.31 |
| MACD | -0.33 | -0.04 |
| Stochastic Oscillator | 15.50 | 12.25 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.